Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan

Respiratory Investigation

Volumn 53, Issue 6, 2015, Pages 279-287

  Taguchi, Yoshio ^a   Ebina, Masahito ^b   Hashimoto, Seishu ^a   Ogura, Takashi ^c   Azuma, Arata ^d   Taniguchi, Hiroyuki ^e   Kondoh, Yasuhiro ^e   Suga, Moritaka ^f   Takahashi, Hiroki ^g   Nakata, Koichiro ^h   Sugiyama, Yukihiko ⁱ   Kudoh, Shoji ^j   Nukiwa, Toshihiro ^j   Betsuyaku, T ^k   Sugawara, Y ^l   Fujiuchi, S ^m   Yamauchi, K ⁿ   Konishi, K ^o   Munakata, M ^p   Kimura, Y ^q   Ishii, Y ^r   Sugiyama, Y ⁱ   Kudoh, K ^s   Saito, T ^t   Yamaguchi, T ^u   Mizoo, A ^v   Nagai, A ^w   Ishizaka, A ^x   Yamaguchi, K ^x   Yoshimura, K ^y   Oritsu, M ^z   Fukuchi, Y ^aa   Takahashi, K ^aa   Kimura, K ^ab   Yoshizawa, Y ^ac   Nagase, T ^ad   Hisada, T ^ae   Ohta, K ^af   Yoshimori, K ^ag   Miyazawa, Y ^ah   Tatsumi, K ^ah   Sasaki, Y ^ai,ay   Taniguchi, M ^aj   Sugita, Y ^ak   Suzuki, E ^al   Saito, Y ^am   Nakamura, H ^an   Chida, K ^ao   Kasamatsu, N ^ap   Hayakawa, H ^aq   Suga numa, H ^ar   Genma, H ^as   Tamura, R ^at   Shirai, T ^au   Shindoh, J ^av   Sato, S ^aw   Taguchi, O ^ax   Ibata, H ^az   Yasui, M ^ba   Nakano, Y ^bb   Ito, M ^bc   Kitada, S ^bc   Kimura, H ^bd   Inoue, Y ^be   Yasuba, H ^bf   Mochizuki, Y ^bg   Horikawa, S ^bh   Suzuki, Y ^bh   Katakami, N ^bi   Tanimoto, Y ^bi   Hitsuda, Y ^bj   Burioka, N ^bj   Sato, T ^bk   Kohno, N ^bl   Yokoyama, A ^bm   Nishioka, Y ^bn   Ueda, N ^bo   Kuwano, K ^bp   Watanabe, K ^bq   Aizawa, H ^br   Kohno, S ^bs   Mukae, H ^bs   Kohrogi, H ^bt   Kadota, J ^bu   Tokimatsu, I ^bu   Miyazaki, E ^bu   Kawabata, M ^bv   more..

^a TENRI HOSPITAL   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e TOSEI GENERAL HOSPITAL   (Japan)

^f SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^g SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h Nakata Clinic ^*  (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j FUKUJUJI HOSPITAL   (Japan)

^k HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^l Kyowakai Obihiro Respiratory Hospital   (Japan)

^m Department of Respiratory Medicine   (Japan)

ⁿ IWATE MEDICAL UNIVERSITY   (Japan)

^o Morioka Tsunagi Onsen Hospital   (Japan)

^p FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^q TOHOKU UNIVERSITY HOSPITAL   (Japan)

^r DOKKYO MEDICAL UNIVERSITY   (Japan)

^s NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^t National Hospital Organization Ibaraki Higashi National Hospital The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^u JR Tokyo General Hospital   (Japan)

^v TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^w TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^x KEIO UNIVERSITY HOSPITAL   (Japan)

^y TORANOMON HOSPITAL   (Japan)

^z JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^aa JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^ab TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^ac TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^ad UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^ae TOKYO TEISHIN HOSPITAL   (Japan)

^af TEIKYO UNIVERSITY HOSPITAL   (Japan)

^ag Japan Anti Tuberculosis Association   (Japan)

^ah CHIBA UNIVERSITY HOSPITAL   (Japan)

^ai SAKURA NATIONAL HOSPITAL   (Japan)

^aj SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^ak General Thoracic Surgery   (Japan)

^al NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^am NISHI NIIGATA CHUO NATIONAL HOSPITAL   (Japan)

^an SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^ao HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ap HAMAMATSU MEDICAL CENTER   (Japan)

^aq National Hospital Organization   (Japan)

^ar Shimada Municipal Hospital   (Japan)

^as Fukuroi Municipal Hospital   (Japan)

^at FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^au Fujinomiya City General Hospital   (Japan)

^av OGAKI MUNICIPAL HOSPITAL   (Japan)

^aw NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^ax MIE UNIVERSITY HOSPITAL   (Japan)

^ay NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^az National Hospital Organization Mie Chuo Medical Center   (Japan)

^ba KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^bb SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^bc TONEYAMA NATIONAL HOSPITAL   (Japan)

^bd NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^be NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^bf TAKATSUKI RED CROSS HOSPITAL   (Japan)

^bg NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

^bh JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^bi OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^bj TOTTORI UNIVERSITY HOSPITAL   (Japan)

^bk Okayama Medical Association   (Japan)

^bl HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^bm TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^bn EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^bo KYUSHU UNIVERSITY HOSPITAL   (Japan)

^bp FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^bq KURUME UNIVERSITY HOSPITAL   (Japan)

^br NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^bs KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^bt OITA UNIVERSITY HOSPITAL   (Japan)

^bu UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^bv Minami Kyushu Hospital   (Japan)

more..

Author keywords

Disease severity; Idiopathic pulmonary fibrosis; Pirfenidone; Progression free survival; Vital capacity

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; BLOOD OXYGEN TENSION; CARBON MONOXIDE LUNG DIFFUSION CAPACITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; JAPAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PULSE OXIMETRY; VITAL CAPACITY; ADULT; AGED; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MORTALITY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PYRIDONES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 84954197768     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.06.002     Document Type: Article

References (43)

1. An Official ATS/ERS/JRS/ALAT Statement Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378:1949-1961.
3. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999, 159:1061-1069.
4. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002, 41:1118-1123.
5. Iwasawa T, Ogura T, Sakai F, et al. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2014, 83:32-38.
6. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
7. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291:367-373.
8. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999, 276:L311-L318.
9. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 289:211-218.
10. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000, 204:119-126.
11. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002, 446:167-176.
12. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590:400-408.
13. Hisatomi K, Mukae H, Sakamoto N, et al. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med 2012, 12:24.
14. Wang Y, Wu Y, Chen J, et al. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology 2013, 126:1-11.
15. Okazaki A, Ohkura N, Fujimura M, et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 2013, 26:603-608.
16. Taniguchi H, Ebina M, Knodoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis: a phase III clinical trial in Japan. Eur Respir J 2010, 35:821-829.
17. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
18. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010, 8:CD003134.
19. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2012, 6:107-114.
20. Takeda Y, Tsujino K, Kijima T, et al. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adher 2014, 8:361-370.
21. Xaubet A, Behr J, Bendstrup E, et al. Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis 2013, 30:249-261.
22. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014, 31:375-391.
23. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
24. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
25. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias. Japanese Respiratory Society's Committee formulating diagnosis and treatment guideline for diffuse lung diseases, editor. Nankodo: Tokyo; 2004. p.63-5 [in Japanese].
26. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011, 12:143.
27. Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22:167-174.
28. Inoue Y, Azuma A, Ogura T, et al. All-case post-marketing surveillance (PMS) of pirfenidone in Japan: clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF). In: ERS Annual Congress Vienna; 2013. Session 345: P3369.
29. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014, 19:740-747.
30. Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014, 52:136-143.
31. Homma S, Sugino K, Sakamoto S. The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig 2015, 53:7-12.
32. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013, 107:1431-1437.
33. Okuda R, Hagiwara E, Endo T, et al. A case of severe idiopathic pulmonary fibrosis effectively treated with pirfenidone. Jpn J Chest Dis 2012, 71:1144-1150.
34. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011, 183:431-440.
35. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001, 164:103-108.
36. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:1084-1090.
37. King TE, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005, 127:171-177.
38. Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011, 12:93.
39. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
40. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 2008, 45:654-656.
41. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:613-620.
42. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011, 364:1503-1512.
43. Inomata M, Kamio K, Azuma A, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res 2014, 15:16.